PF-08046054 by Pfizer for Solid Tumor: Likelihood of Approval

PF-08046054 is under clinical development by Pfizer and currently in Phase I for Solid Tumor.

Common oral anticoagulant rivaroxaban linked to highest risk of bleeding complications

When diagnosed with a blood clot or atrial fibrillation, patients are often prescribed anticoagulants, or blood thinners, to prevent a future clot.

December 14, 2023

Lilly again hires from within for CFO post, elevating 23-year company veteran

The world’s most valuable drugmaker has a new finance chief. Lucas Montarce stepped into the chief financial officer role at Eli Lilly, Sign up to

September 10, 2024

Extended-release ketamine tablets offer new hope for treatment-resistant depression

The BEDROC trial found that extended-release ketamine tablets (R-107) significantly improve depressive symptoms in treatment-resistant depression patients, with the 180 mg dose showing the most

June 26, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.